Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension

被引：0
作者：
Batyraliev, T. A. [1 ]
Makhmutkhodzhaev, S. A.
Ekinci, E.
Pataraya, S. A.
Pershukov, I. V.
Sidorenko, B. A.
Preobrazhensky, D. V.
机构：
[1] Sani Konukoglu Univ, Med Ctr, Gaziantep, Turkey
[2] Presidential Med Ctr Russia, Moscow 121356, Russia
来源：
KARDIOLOGIYA | 2007年 / 47卷 / 07期
关键词：
pulmonary arterial hypertension; treatment; endothelin; endothelin receptor blockers; bosentan; sitaxsentan; ambrisentan;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In a series of articles the authors discuss literature data concerning epidemiology of pulmonary arterial hypertension (PAH), its modern classification; peculiarities of its pathogenesis and treatment in various diseases and conditions. in the eleventh communication the authors discuss literature data related to the role of endothelin system in pathogenesis of primary (idiopathic) PAH, as well as PAH associated with diffuse diseases of connective tissue and congenital heart disease. This communication also containes presentation of clinical pharmacology of three available endothelin receptor blockers-bosentan, sitaxsentan, ambrisentan, and analysis of results of randomized controlled trials of efficacy and safety of these agents in patients with idiopathic PAH and PAH associated with diffuse diseases of connective tissue and congenital heart disease.
引用
收藏
页码：73 / 82
页数：10
相关论文
共 41 条
[1]   Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH):: randomised, double-blind, placebo-controlled trial [J].
Anand, I ;
McMurray, J ;
Cohn, JN ;
Konstam, MA ;
Notter, T ;
Quitzau, K ;
Ruschitzka, F ;
Lüscher, TF .
LANCET, 2004, 364 (9431) :347-354
[2]   Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension [J].
Badesch, DB ;
Bodin, F ;
Channick, RN ;
Frost, A ;
Rainisio, M ;
Robbins, IM ;
Roux, S ;
Rubin, LJ ;
Simonneau, G ;
Sitbon, O ;
Tapson, VF .
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (04) :227-246
[3]   Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].
Badesch, DB ;
Abman, SH ;
Ahearn, GS ;
Barst, RJ ;
McCrory, DC ;
Simonneau, G ;
McLaughlin, VV .
CHEST, 2004, 126 (01) :35S-62S
[4]   Sitaxsentan therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
Langleben, D ;
Frost, A ;
Horn, EM ;
Oudiz, R ;
Shapiro, S ;
McLaughlin, V ;
Hill, N ;
Tapson, VF ;
Robbins, IM ;
Zwicke, D ;
Duncan, B ;
Dixon, RAF ;
Frumkin, LR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447
[5]   Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study [J].
Barst, RJ ;
Rich, S ;
Widlitz, A ;
Horn, EM ;
McLaughlin, V ;
McFarlin, J .
CHEST, 2002, 121 (06) :1860-1868
[6]   Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan [J].
Barst, Robyn J. ;
Langleben, David ;
Badesch, David ;
Frost, Adaani ;
Lawrence, E. Clinton ;
Shapiro, Shelley ;
Naeije, Robert ;
Galie, Nazzareno .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (10) :2049-2056
[7]   Endothelin antagonists [J].
Benigni, A ;
Remuzzi, G .
LANCET, 1999, 353 (9147) :133-138
[8]   Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension [J].
Channick, Richard N. ;
Olschewski, Horst ;
Seeger, Werner ;
Staub, Ted ;
Voswinckel, Robert ;
Rubin, Lewis J. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 48 (07) :1433-1437
[9]   Endothelin receptor antagonists in pulmonary arterial hypertension [J].
Channick, RN ;
Sitbon, O ;
Barst, RJ ;
Manes, A ;
Rubin, LJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) :62S-67S
[10]   Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].
Channick, RN ;
Simonneau, G ;
Sitbon, O ;
Robbins, IM ;
Frost, A ;
Tapson, VF ;
Badesch, DB ;
Roux, S ;
Rainisio, M ;
Bodin, F ;
Rubin, LJ .
LANCET, 2001, 358 (9288) :1119-1123
12345